ArticleDiscover oncology2026
A case of breast acinar cell carcinoma combined with metaplastic carcinoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast acinar cell carcinoma (AcCC) is a rare subtype of triple-negative breast cancer. Its histological origin remains controversial, and it exhibits poor sensitivity to conventional chemotherapy. High-grade transformation and co-existence with matrix-producing metaplastic carcinoma are uncommon, and their clinical and molecular genetic features are poorly understood. CASE PRESENTATION: A 42-year-old woman incidentally discovered a breast mass for 10 days. Ultrasound revealed an irregular hypoechoic lesion in the upper inner quadrant of the left breast, classified as BI-RADS 4b, leading to a clinical diagnosis of breast cancer. Microscopically, the tumor comprised two distinct components. Component one exhibited tubular or solid nested patterns with eosinophilic secretions in lumina; some cells were amphophilic, and focal areas showed marked high-grade transformation with significant nuclear atypia. Component two featured tumor cell cords and nests distributed within a chondromyxoid stromal matrix. Immunophenotypically, tumor cells in both components diffusely and strongly expressed S-100, GATA3, AE1/AE3, and EMA. Component one expressed Lysozyme (LYS) and α1-antichymotrypsin (AACT). Both components were negative for ER, PR, HER2, CK5/6, CD117, P63, and Collagen IV. The Ki-67 proliferation index was approximately 10% in the low-grade areas of component one, reached about 30% in its high-grade areas, and was approximately 70% in component two. Molecular genetics: Next-generation sequencing detected a somatic frameshift mutation in the TP53 gene with a variant allele frequency of 36.51%, as well as germline variants in APC, ATM, BRCA1, BRCA2, and others.
conclusionThis report describes a breast tumor exhibiting concurrent features of AcCC and matrix-producing metaplastic carcinoma, summarizing its immunophenotypic characteristics and molecular genetic alterations. This information may provide diagnostic insights for future encounters with similar cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.